CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues

被引：0
|
作者：
Giao Q. Phan
Jeffrey S. Weber
Vernon K. Sondak
机构：
[1] H. Lee Moffitt Cancer Center,Division of Cutaneous Oncology
[2] H. Lee Moffitt Cancer Center,The Donald A. Adam Comprehensive Melanoma Research Center
[3] University of South Florida College of Medicine,Department of Oncologic Sciences
[4] University of South Florida College of Medicine,Department of Surgery
来源：
Annals of Surgical Oncology | 2008年 / 15卷
关键词：
Immune-related Adverse Events (IRAEs); Ipilimumab; Tremelimumab; Hypophysitis; Infliximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3014 / 3021
页数：7
相关论文
共 50 条
  • [31] Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
    Kwek, Serena S.
    Dao, Vinh
    Roy, Ritu
    Hou, Yafei
    Alajajian, David
    Simko, Jeffrey P.
    Small, Eric J.
    Fong, Lawrence
    JOURNAL OF IMMUNOLOGY, 2012, 189 (07): : 3759 - 3766
  • [32] CTLA-4 Blockade for Melanoma: Past, Present and Future
    Wolchok, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 7 - 7
  • [33] Autoimmune hypophysitis: Autoantigens and association with CTLA-4 blockade
    Caturegli, Patrizio
    ANNALES D ENDOCRINOLOGIE, 2012, 73 (02) : 78 - 78
  • [34] CTLA-4 Blockade Resistance after Relatlimab and Nivolumab
    Menzies, Alexander M.
    da Silva, Ines Pires
    Trojaniello, Claudia
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (17): : 1668 - 1669
  • [35] CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?
    Thomas, Anish
    Hassan, Raffit
    LANCET ONCOLOGY, 2017, 18 (09): : 1150 - 1151
  • [36] Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update
    Kaehler, Katharina C.
    Hassel, Jessica C.
    Heinzerling, Lucie
    Loquai, Carmen
    Thoms, Kai-Martin
    Ugurel, Selma
    Zimmer, Lisa
    Gutzmer, Ralf
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, : 582 - 609
  • [37] Benefiting from CTLA-4 blockade—a genetic rationale
    Alessia Errico
    Nature Reviews Clinical Oncology, 2015, 12 (1) : 4 - 4
  • [38] CTLA-4 blockade in the treatment of rheumatoid arthritis: an update
    Cutolo, Maurizio
    Sulli, Alberto
    Paolino, Sabrina
    Pizzorni, Carmen
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (04) : 417 - 425
  • [39] Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Peggs, Karl S.
    Quezada, Sergio A.
    Chambers, Cynthia A.
    Korman, Alan J.
    Allison, James P.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (08): : 1717 - 1725
  • [40] Bilateral internuclear Ophthalmoplegia with Immune Checkpoint Blockade by CTLA-4 and PD1-Antibodies in Patients with Malignant Melanoma
    Maikranz, V.
    Hayani, E.
    Saloga, J.
    Grabbe, S.
    Loquai, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 74 - 75
12345